Skip to content

CGNI

Cardiogeni Plc

Access


ISIN

GB00BTBLFC12

Bid

20.00

Mid

25.00

Ask

30.00

Key Information

Price Change
0.00%
Year High
60.00
Year Low
25.00
Last Trade
5 Feb 25
Market Cap
£21.34M
Par
0.01
Bid
20.00
Mid Price
25.00
Ask
30.00
Instrument Type
Ordinary Shares
MIFID Status
MTF
Tradable Securities
85.35M
Sector
Healthcare

Prices in GBX except for Market Cap in GBP

About Cardiogeni Plc

Founded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group’s platform technology enables the creation of unique (living) cells that are engineered with a therapeutic function. The Group’s lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery.The Group’s novel technology was developed in-house by Professor Sir Martin Evans and is protected by a portfolio of ~100 international patents and trademarks. CLXR-001 targets heart failure and consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration, which will affect 1 in 4 people in their lifetime and is not reversible or curable. This technology is expected to regenerate the damaged heart tissue restoring heart function and improving life expectancy and quality of life. CLXR-001 has successfully completed an EU Phase II clinical trial in which patients showed a statistically significant (P<0.05) improvement in all parameters including heart function, reduction in heart scarring and an improvement in quality of life.

Cardiogeni PlcAccess

Today's Trading

VolumeNumber TradesValue Trades (GBP )
000.00

Latest Trades

DateVolumePrice (GBX)Value (GBP)

05 Feb 25

08:02

22041.0090.20

04 Feb 25

10:56

20,00025.005,000.00

03 Feb 25

11:34

15066.0099.00

03 Feb 25

10:18

15066.0099.00
View all trades

Latest Announcements & Notices

DateTitle
No announcements or notices
View all announcementsView all notices

Address

Registered Address

Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford-Upon-Avon, Warwickshire, CV37 7GZ, United Kingdom

Email

info@cardiogeniplc.com

Phone

+44(0) 1789 576047

Contacts

Corporate Adviser

First Sentinel Corporate Finance, 72 Charlotte Street, London , W1T 4QQ, United Kingdom

Registrar

Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom
Loading...

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2025. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal